# Longitudinal Imaging Biomarkers of Disease Progression in DLB

> **NIH NIH U01** · MAYO CLINIC ROCHESTER · 2021 · $1,359,564

## Abstract

PROJECT SUMMARY / ABSTRACT
 Dementia with Lewy bodies (DLB) is a clinical syndrome characterized by the presence of Lewy body
disease (LBD), but additional Alzheimer's disease (AD)-related pathology is also common in patients with
DLB. Although the impact of each of these two pathologies on the clinical disease progression is not fully
understood, many DLB patients may benefit from treatments that target both AD and LBD-related
pathological processes. To prepare for these clinical trials in DLB, we need robust and reliable biomarkers
that can track disease progression, particularly the progression of both LBD- and AD-related pathologies.
We propose multi-modal imaging biomarkers of pathological processes commonly present in patients with
DLB to detect disease progression. We propose to establish a longitudinal cohort of patients with DLB and
acquire clinical and multi-modal imaging biomarker data to model the longitudinal imaging biomarker
changes with respect to clinical disease progression in DLB. In Aim 1, we propose to determine whether
LBD-related dopaminergic loss on SPECT, and AD pathophysiology measured with higher amyloid-β
deposition on PET and AD-signature atrophy on MRI is associated with the rate of clinical disease
progression, cognitive decline and survival in DLB; In Aim 2, we will determine whether these longitudinal
changes in imaging biomarkers and clinical outcomes, and their associations are modified by genetic, sex-
based, and cerebrovascular disease-related features. In Aim 3, we will determine the pattern of a tau ligand
AV-1451 uptake in DLB compared to controls and its relationship to the rate of change in imaging
biomarkers and clinical disease progression. Finally, we will determine the pathologic basis of the
biomarker changes in DLB in autopsied patients, which is the gold standard for validating imaging
biomarkers in Aim 4. In addition to these aims that focus on hypothesis testing, we will respond to RFA-NS-
16-022 by collecting whole blood, plasma, serum, CSF, and urine samples, clinical and harmonized
neuroimaging data longitudinally; DNA and peripheral blood mononuclear cells from a prospective cohort of
DLB patients, and submit them to the PDBP.

## Key facts

- **NIH application ID:** 10241259
- **Project number:** 5U01NS100620-05
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Bradley F Boeve
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,359,564
- **Award type:** 5
- **Project period:** 2017-09-25 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10241259

## Citation

> US National Institutes of Health, RePORTER application 10241259, Longitudinal Imaging Biomarkers of Disease Progression in DLB (5U01NS100620-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10241259. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*